CLL and COVID-19: Case Report of Use of Convalescent Plasma Plus Remdesivir

Description

Due to the impairment of humoral responses in patients with chronic lymphocytic leukemia (CLL), there appears to be a higher risk of death from COVID-19. Carla Schenker, MD, and colleagues from the University of Bern, Switzerland, described a patient with CLL and COVID-19 who experienced rapid clinical improvement followed by relapse after receiving convalescent plasma and the antiviral medication remdesivir. This case report was published in the British Journal of Haematology.